Unicycive Therapeutics' (UNCY) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Unicycive Therapeutics' stock has been given a "sell (D-)" rating by Weiss Ratings, indicating a negative outlook for investors.
• The company's stock experienced a 3.0% increase on Wednesday, reaching $4.77, though it remains significantly lower than its 12-month high of $11.00.
• Analysts have varying views, with one rating it as a Strong Buy, but the consensus rating is a "Moderate Buy" with an average price target of $57.00.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

UNCY has been the subject of several other reports. Benchmark raised their target price on Unicycive Therapeutics to $21.00 and gave the company a "speculative buy" rating in a research note on Monday, September 15th. Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, September 26th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $57.00.

Unicycive Therapeutics Stock Up 3.0%

Shares of Unicycive Therapeutics stock traded up $0.14 during trading on Wednesday, reaching $4.77. The company's stock had a trading volume of 267,251 shares, compared to its average volume of 513,633. The company has a market capitalization of $84.24 million, a P/E ratio of -1.16 and a beta of 1.86. The business has a 50 day moving average price of $4.23 and a 200-day moving average price of $5.27. Unicycive Therapeutics has a 12-month low of $3.50 and a 12-month high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.18. Research analysts predict that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 14.0% during the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock valued at $104,000 after purchasing an additional 21,525 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in Unicycive Therapeutics during the 2nd quarter valued at approximately $55,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.